{"id":1911,"date":"2007-08-29T10:47:28","date_gmt":"2007-08-29T09:47:28","guid":{"rendered":"http:\/\/www.ethicalquote.com\/index.php\/2007\/08\/29\/le-fardeau-de-l%e2%80%99innovation-rapport-covalence-secteur-pharmaceutique-2007\/"},"modified":"2007-08-29T10:49:03","modified_gmt":"2007-08-29T09:49:03","slug":"le-fardeau-de-linnovation-rapport-covalence-secteur-pharmaceutique-2007","status":"publish","type":"post","link":"https:\/\/www.covalence.ch\/index.php\/2007\/08\/29\/le-fardeau-de-linnovation-rapport-covalence-secteur-pharmaceutique-2007\/","title":{"rendered":"Le fardeau de l\u2019innovation – Rapport Covalence secteur pharmaceutique 2007"},"content":{"rendered":"

\"070829_pharmareport1.jpg\"<\/a>Les risques \u00e9thique li\u00e9s \u00e0\u00a0 l\u2019innovation p\u00e8sent de plus en plus sur la r\u00e9putation des firmes pharmaceutiques, indique un rapport publi\u00e9 le 29 ao\u00e0\u00bbt 2007 par la soci\u00e9t\u00e9 genevoise Covalence, Covalence Pharmaceutical Industry Report 2007<\/em><\/a>. Ces risques li\u00e9s \u00e0\u00a0 l\u2019innovation touchent les droits de propri\u00e9t\u00e9 intellectuelle, le prix de vente des m\u00e9dicaments, les essais cliniques, les effets secondaires des produits et l\u2019information au public. En termes de r\u00e9putation \u00e9thique, l\u2019innovation semble apporter plus d\u2019inconv\u00e9nients que d\u2019avantages aux compagnies pharmaceutiques orient\u00e9es sur la recherche & d\u00e9veloppement. De juillet 2006 \u00e0\u00a0 juillet 2007, l\u2019industrie pharmaceutique ne se classe que neuvi\u00e8me sur dix industries dans la cotation \u00e9thique de Covalence (EthicalQuote). Alors que des annonces spectaculaires sont entendues chaque jour, et que l\u2019innovation est surveill\u00e9es par des observateurs soup\u00e0\u00a7onneux, les entreprises pharmaceutiques se doivent de d\u00e9velopper et inventer de nouvelles mani\u00e8res d\u2019\u00e0\u00aatre reconnues comme durables, en utilisant les le\u00e0\u00a7ons apprises durant le temps des pionniers. Au sein de l\u2019industrie<\/span> (14 parmi les plus grandes pharmaceutiques en capitalisation boursi\u00e8re<\/span>), les courbes de cotation \u00e9thique (\u201cEthicalQuote\u201d, de 2002 \u00e0\u00a0 juillet 2007) font appara\u00e0\u00aetre<\/span> GlaxoSmithKline en t\u00e0\u00aate devant<\/span> Bristol Myers Squibb et Johnson & Johnson, alors que<\/span> Takeda et Schering Plough ferment la marche<\/span>. Dans le classement de performance rapport\u00e9e (informations positives seulement; sur les douze derniers mois), <\/span>Pfizer arrive en t\u00e0\u00aate, suivi de Abbott, Novartis et AstraZeneca. > Continue<\/a>.<\/span><\/p>\n

Publication: Covalence Press Release | Country: Global | Company: <\/span>Abbott, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck and Co, Novartis, Pfizer, Roche, Sanofi aventis, Schering Plough, Takeda<\/a><\/span> <\/span>| <\/span>Source: Covalence<\/a><\/span><\/p>\n","protected":false},"excerpt":{"rendered":"

Les risques \u00e9thique li\u00e9s \u00e0\u00a0 l\u2019innovation p\u00e8sent de plus en plus sur la r\u00e9putation des firmes pharmaceutiques, indique un rapport publi\u00e9 le 29 ao\u00e0\u00bbt 2007 par la soci\u00e9t\u00e9 genevoise Covalence, Covalence Pharmaceutical Industry Report 2007. Ces risques li\u00e9s \u00e0\u00a0 l\u2019innovation touchent les droits de propri\u00e9t\u00e9 intellectuelle, le prix de vente des m\u00e9dicaments, les essais cliniques,…<\/p>\n","protected":false},"author":665,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_exactmetrics_skip_tracking":false,"_exactmetrics_sitenote_active":false,"_exactmetrics_sitenote_note":"","_exactmetrics_sitenote_category":0,"wds_primary_category":0,"wds_primary_post_series":0,"footnotes":""},"categories":[2],"tags":[],"post_series":[],"class_list":["post-1911","post","type-post","status-publish","format-standard","hentry","category-publications","entry","no-media"],"_links":{"self":[{"href":"https:\/\/www.covalence.ch\/index.php\/wp-json\/wp\/v2\/posts\/1911","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.covalence.ch\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.covalence.ch\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.covalence.ch\/index.php\/wp-json\/wp\/v2\/users\/665"}],"replies":[{"embeddable":true,"href":"https:\/\/www.covalence.ch\/index.php\/wp-json\/wp\/v2\/comments?post=1911"}],"version-history":[{"count":0,"href":"https:\/\/www.covalence.ch\/index.php\/wp-json\/wp\/v2\/posts\/1911\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.covalence.ch\/index.php\/wp-json\/wp\/v2\/media?parent=1911"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.covalence.ch\/index.php\/wp-json\/wp\/v2\/categories?post=1911"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.covalence.ch\/index.php\/wp-json\/wp\/v2\/tags?post=1911"},{"taxonomy":"post_series","embeddable":true,"href":"https:\/\/www.covalence.ch\/index.php\/wp-json\/wp\/v2\/post_series?post=1911"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}